TransCode Therapeutics Says TTX-MC138 Met Phase 1a Safety Endpoint
TransCode Therapeutics reported that its TTX-MC138 met the primary safety endpoint in a Phase 1a trial.
TransCode Therapeutics reported that its TTX-MC138 met the primary safety endpoint in a Phase 1a trial.